Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms

European Journal of Cell Biology

Volumn 90, Issue 8, 2011, Pages 657-664

  Yamasaki, Daisuke ^a   Kawabe, Natsuko ^a   Nakamura, Hitomi ^a   Tachibana, Keisuke ^a   Ishimoto, Kenji ^a   Tanaka, Toshiya ^b   Aburatani, Hiroyuki ^b   Sakai, Juro ^b   Hamakubo, Takao ^b   Kodama, Tatsuhiko ^b   Doi, Takefumi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

AKT; Antiproliferation; C terminal modulator protein (CTMP); Fenofibrate; Peroxisome proliferator activated receptor (PPAR) alpha

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; BEZAFIBRATE; C TERMINAL MODULATOR PROTEIN; CLOFIBRATE; CLOFIBRIC ACID; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 79957669555     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2011.02.005     Document Type: Article

References (36)

1. Backes J.M., Gibson C.A., Ruisinger J.F., Moriarty P.M. Fibrates: what have we learned in the past 40 years?. Pharmacotherapy 2007, 27:412-424.
2. Brown P.J., Stuart L.W., Hurley K.P., Lewis M.C., Winegar D.A., Wilson J.G., Wilkison W.O., Ittoop O.R., Willson T.M. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg. Med. Chem. Lett. 2001, 11:1225-1227.
3. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N.B., Gilliland D.G., Druker B.J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
4. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., De Placido S., Bianco A.R., Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 2001, 7:1459-1465.
5. Cornu-Chagnon M.C., Dupont H., Edgar A. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam. Appl. Toxicol. 1995, 26:63-74.
6. Du K., Tsichlis P.N. Regulation of the Akt kinase by interacting proteins. Oncogene 2005, 24:7401-7409.
7. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30:193-204.
8. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
9. Goetze S., Eilers F., Bungenstock A., Kintscher U., Stawowy P., Blaschke F., Graf K., Law R.E., Fleck E., Grafe M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophys. Res. Commun. 2002, 293:1431-1437.
10. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 1993, 53:3186-3192.
11. Grabacka M., Plonka P.M., Urbanska K., Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin. Cancer Res. 2006, 12:3028-3036.
12. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med. 1995, 332:1256-1261.
13. Hwang S.K., Kwon J.T., Park S.J., Chang S.H., Lee E.S., Chung Y.S., Beck G.R., Lee K.H., Piao L., Park J., Cho M.H. Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther. 2007, 14:1721-1730.
14. Jiao H.L., Campbell N. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol. Appl. Pharmacol. 2002, 185:172-179.
15. Kubota T., Yano T., Fujisaki K., Itoh Y., Oishi R. Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt. Apoptosis 2005, 10:349-358.
16. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
17. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T., Fan S.T., Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
18. Losel R.M., Falkenstein E., Feuring M., Schultz A., Tillmann H.C., Rossol-Haseroth K., Wehling M. Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev. 2003, 83:965-1016.
19. Lupi M., Cappella P., Matera G., Natoli C., Ubezio P. Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemother. Pharmacol. 2006, 57:443-457.
20. Maiguma T., Fujisaki K., Itoh Y., Makino K., Teshima D., Takahashi-Yanaga F., Sasaguri T., Oishi R. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 367:289-296.
21. Maira S.M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., Hemmings B.A. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001, 294:374-380.
22. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996, 334:693-699.
23. Minami T., Tachibana K., Imanishi T., Doi T. Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur. J. Biochem. 1998, 258:879-889.
24. Munro E., Patel M., Chan P., Betteridge L., Gallagher K., Schachter M., Wolfe J., Sever P. Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis. Cardiovasc. Res. 1994, 28:615-620.
25. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
26. Pang R.W., Joh J.W., Johnson P.J., Monden M., Pawlik T.M., Poon R.T. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 2008, 15:962-971.
27. Panigrahy D., Kaipainen A., Huang S., Butterfield C.E., Barnes C.M., Fannon M., Laforme A.M., Chaponis D.M., Folkman J., Kieran M.W. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:985-990.
28. Saidi S.A., Holland C.M., Charnock-Jones D.S., Smith S.K. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol. Cancer 2006, 5:13.
29. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1996, 1302:93-109.
30. Tachibana K., Kobayashi Y., Tanaka T., Tagami M., Sugiyama A., Katayama T., Ueda C., Yamasaki D., Ishimoto K., Sumitomo M., Uchiyama Y., Kohro T., Sakai J., Hamakubo T., Kodama T., Doi T. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl. Recept. 2005, 3:3.
31. Tachibana K., Takeuchi K., Inada H., Yamasaki D., Ishimoto K., Tanaka T., Hamakubo T., Sakai J., Kodama T., Doi T. Regulation of the human SLC25A20 expression by peroxisome proliferator-activated receptor alpha in human hepatoblastoma cells. Biochem. Biophys. Res. Commun. 2009, 389:501-505.
32. Thomas M.B., O'Beirne J.P., Furuse J., Chan A.T., Abou-Alfa G., Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann. Surg. Oncol. 2008, 15:1008-1014.
33. Varet J., Vincent L., Mirshahi P., Pille J.V., Legrand E., Opolon P., Mishal Z., Soria J., Li H., Soria C. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell. Mol. Life Sci. 2003, 60:810-819.
34. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., Vinci F., Chiappetta G., Tsichlis P., Bellacosa A., Fusco A., Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 2002, 8:1136-1144.
35. von Daniken A., Lutz W.K., Schlatter C. Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate. Toxicol. Lett. 1981, 7:305-310.
36. Yamasaki F., Hama S., Yoshioka H., Kajiwara Y., Yahara K., Sugiyama K., Heike Y., Arita K., Kurisu K. Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line. Cancer Chemother. Pharmacol. 2003, 51:271-283.